While revenues in Q3 were much higher than initially anticipated, We view this outperformance as an acceleration, not as an aberration. During Q3, we got to a point on our growth curve we had originally assumed was at least another quarter or 2 out, but we do not believe that this is one time revenue. As such, as Lee mentioned earlier, We are raising our revenue guidance for the full year 2023 and we now expect that revenues will be in the range of $615,000,000 to $625,000,000 Compared with our most recent increase in revenue guidance into the $540,000,000 to $550,000,000 range, the original revenue guidance for 2023, I'll remind everyone, it was $500,000,000 to $510,000,000 The increased revenue guidance range would represent year over year top line growth Of about 40% on an as reported basis. However, when removing the $75,000,000 of mass COVID testing from our 2022 revenue baseline considering that we have not received any material mass COVID testing revenues thus far in 2023, then we would expect to be looking at top line growth of nearly 70% when comparing full year 2023 with full year 2022. We are also increasing our guidance for adjusted EBITDA the range of $50,000,000 to $55,000,000 up from our recent guidance of $48,000,000 to $53,000,000 which had already been raised last quarter from our initial 2023 guidance $45,000,000 to $50,000,000 With respect to 2024, it's too early for me to provide any specific details at this time.